In The News (Full Edition)

Link between diesel exhaust and risk of Parkinson’s discovered

Researchers have uncovered the process by which air pollution can damage brain cells, leading to an increased risk of Parkinson’s disease. Chemicals found in diesel fuel reduced autophagic flux, which is a major pathway implicated in neurodegeneration.


A new UCLA study in zebrafish has identified the process by which air pollution can damage brain cells, potentially contributing to Parkinson’s disease.


Published in the peer-reviewed journal Toxicological Sciences, the findings show that chemicals in diesel exhaust can trigger the toxic buildup of a protein in the brain called alpha-synuclein, which is commonly seen in people with the disease...

Parkinson's

2020-05-20

Link between diesel exhaust and risk of Parkinson’s discovered
COVID-19 Presents Distinct Challenges, and Opportunities, with Parkinson’s

People with Parkinson’s disease can face “hidden sorrows” during the COVID-19 pandemic, like increased stress and limits on physical activity, that could worsen their symptoms. But ways exist to mitigate these “less visible” threats of social distancing and other changes in daily routines.


Indeed, the pandemic may facilitate wider access to helpful online resources, and could open new opportunities for research, two neurologists suggest...

Parkinson's

2020-04-08

COVID-19 Presents Distinct Challenges, and Opportunities, with Parkinson’s
7 Ways to Make Your Home Safer

There are several things you can do to improve your daily routine while living with Parkinson’s. Many of these changes include small adjustments and renovations to your home, which should be your safe place now more than ever.


To help you with all these overwhelming changes, we’ve put together a list of tips based on suggestions from the Michael J. Fox Foundation. These tips will help you improve your life and safety while living and coping with Parkinson’s symptoms...

Parkinson's

2020-03-27

7 Ways to Make Your Home Safer
'Natural killer' cells could halt Parkinson's progression

Researchers at the University of Georgia's Regenerative Bioscience Center and their colleagues have found that "natural killer" white blood cells could guard against the cascade of cellular changes that lead to Parkinson's disease and help stop its progression...

Parkinson's

2020-03-18

'Natural killer' cells could halt Parkinson's progression
Does an Exercise Lifestyle Before Parkinson’s Onset Affect Progression?

“When it comes to eating right and exercising, there is no ‘I’ll start tomorrow.’ Tomorrow is disease.” –V.L. Allineare

In December, I asked members of the Parkinson’s News Today Forums if anyone was an athlete prior to their diagnosis. By “athlete,” I mean a recreational athlete who consistently trains and challenges themselves, not elite or Olympic-caliber athletes.

The benefits of exercise for people already diagnosed with Parkinson’s are well-known, but I’ve been wondering whether an active lifestyle before disease onset makes a difference in the rate of symptom progression. Could consistent exercise before Parkinson’s onset be an investment in an individual’s future quality of life?...

Parkinson's

2020-03-03

Does an Exercise Lifestyle Before Parkinson’s Onset Affect Progression?
CDNF Safe in Advanced Parkinson’s, Trial Results Show

Treatment with cerebral dopamine neurotrophic factor (CDNF), developed by Herantis Pharma, was safe and well-tolerated among patients with advanced-stage Parkinson’s disease, according to topline results from a Phase1/2 clinical trial.

The therapy also showed promise in measures of dopaminergic function in some patients...

Parkinson's

2020-02-27

CDNF Safe in Advanced Parkinson’s, Trial Results Show
FDA Clears Way for Phase 2 Trial of AV-101 for Levodopa-Induced Dyskinesia

VistaGen Therapeutics will begin a Phase 2 clinical trial to evaluate its lead candidate AV-101 as a potential treatment to reduce dyskinesia (abnormal involuntary movements) induced by levodopa in patients with Parkinson’s disease, after the U.S. Food and Drug Administration (FDA) cleared the company’s investigational new drug (IND) application.

Parkinson’s is characterized by the loss of neurons that produce the neurotransmitter dopamine. Treatment with levodopa, or L-DOPA — a precursor to dopamine — is one of the gold standards for Parkinson’s. However, as the disease progresses, patients need larger doses...

Parkinson's

2020-02-04

FDA Clears Way for Phase 2 Trial of AV-101 for Levodopa-Induced Dyskinesia
‘Keep On Moving’ Video Marks World Parkinson’s Day This Saturday

To heighten awareness of Parkinson’s disease (PD) and inspire patients and their families, Bial Pharmaceuticals has produced a short video to mark World Parkinson’s Day this Saturday, April 11.


Called “Keep On Moving,” the production also seeks to destigmatize the neurodegenerative disease and show the diversity and accomplishments of people living with Parkinson’s. It’s part of a global campaign that Bial, based in Portugal, launched four years ago...

Parkinson's

2020-04-10

‘Keep On Moving’ Video Marks World Parkinson’s Day This Saturday
Foliglurax Fails to Minimize Long-term Use Side Effects of Levodopa, Phase 2 Trial Shows

Despite being safe and well-tolerated, foliglurax (PTX002331), an investigational therapy for Parkinson’s disease, failed to significantly reduce some of the effects associated with long-term use of levodopa, including its “wearing-off” effect and motor complications, according to data from a Phase 2 clinical trial.


As a result, Lundbeck, the company that currently holds the therapy’s development and commercial rights, has decided to terminate its development program and to write-down foliglurax’s current value of €100 million (about $108 million)...

Parkinson's

2020-04-03

Foliglurax Fails to Minimize Long-term Use Side Effects of Levodopa, Phase 2 Trial Shows
Possible Link Found Between Vitamin B12 Levels and Dementia in Parkinson’s

People who have higher levels of vitamin B12 in their blood when they’re diagnosed with Parkinson’s disease may be less likely to develop dementia, a study suggests.


The study, “Higher vitamin B12 level at Parkinson’s disease diagnosis is associated with lower risk of future dementia,” was published in Parkinsonism & Related Disorders.


Dementia describes a group of symptoms in which memory and cognitive abilities become impaired enough to affect daily life. Dementia can be part of the non-motor symptoms associated with Parkinson’s disease; it is most common among people who are older and/or have had Parkinson’s symptoms for longer...

Parkinson's

2020-03-27

Possible Link Found Between Vitamin B12 Levels and Dementia in Parkinson’s
Natural Killer Immune Cells Limit Parkinson’s Progression, Study Finds

Immune cells known as “natural killer” (NK) cells appear to fight the cellular changes that lead to conditions such as Parkinson’s disease. Understanding how they do this may lead to new therapies for the neurodegenerative disorder, according to a study from the University of Georgia.


The study, “NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy,” was published in the journal Proceedings of the National Academy of Sciences...

Parkinson's

2020-03-17

Natural Killer Immune Cells Limit Parkinson’s Progression, Study Finds
Older Parkinson’s Patients Often Wrongly Given Antipsychotics, Study Says

More than one-third of older people with Parkinson’s disease in long-term care who experienced therapy-related psychosis were prescribed antipsychotic medications considered inappropriate under current guidelines, a study found.

Those with dementia or using antidepressants were more likely to be given these medicines. 

Concerted efforts are needed to curb the use of inappropriate antipsychotics, which may worsen Parkinsonian symptoms, the researchers said...

Parkinson's

2020-03-02

Older Parkinson’s Patients Often Wrongly Given Antipsychotics, Study Says
First Patient Dosed in Phase 2 Trial of Oral Treatment to Ease Inflammation in Parkinson’s

Alkahest announced the dosing of a first patient in the Phase 2 trial for its Parkinson’s therapy AKST4290, an oral tablet aiming to ease the inflammation that can aggravate disease symptoms.

The efficacy and safety trial, called AKST4290-211 or TEAL (2019-001657-42), will measure AKST4290’s benefits in motor function and activities relevant to daily life in treated patients relative to those given a placebo, the company said in a press release.

AKST4290 is designed to block the protein eotaxin. Eotaxin accumulates in the bloodstream as we age, and is believed to cause increased inflammation...

Parkinson's

2020-02-06

First Patient Dosed in Phase 2 Trial of Oral Treatment to Ease Inflammation in Parkinson’s
FDA Extends Abbott’s Infinity DBS System Approval to Target Additional Brain Region

The U.S. Food and Drug Administration (FDA) has expanded Abbott’s Infinity Deep Brain Stimulation (DBS) system approval to target a brain region critical for motor functions — the globus pallidus — as a way to lessen motor symptoms in Parkinson’s disease patients who still show impairments after medication.

This extended approval makes Abbott’s Infinity the only directional DBS system approved to target all three main brain regions used to treat Parkinson’s, essential tremor and movement disorders: the globus pallidus, the subthalamic nucleus, and the ventral intermediate nucleus...

Parkinson's

2020-01-28

FDA Extends Abbott’s Infinity DBS System Approval to Target Additional Brain Region
$70 Million Raised for Neuron Replacement Therapy Techniques to Treat Parkinson’s

Aspen Neuroscience has raised $70 million to advance the development of  Parkinson’s disease therapies using patients’ own cells.


The products, ANPD001 and ANPD002, are the first-ever Parkinson’s treatments designed to use a patient’s own cells as a replacement to restore neuronal function and to modify disease progression. This approach is referred to as an autologous neuron replacement therapy...

Parkinson's

2020-04-08

$70 Million Raised for Neuron Replacement Therapy Techniques to Treat Parkinson’s
Dopamine Infused Directly to Brain Eased Symptoms in Monkeys

An oxygen-free (anaerobic) formulation of dopamine infused directly into the brain of monkeys with induced Parkinson’s safely improved both their motor and cognitive symptoms, according to a new study.


These findings support a proof-of-concept clinical trial of this treatment approach, adapted to people with the disease...

Parkinson's

2020-03-30

Dopamine Infused Directly to Brain Eased Symptoms in Monkeys
Study to Test MRI Technique for Possible Early Parkinson’s Diagnosis

A clinical study will test the potential of a specific magnetic resonance imaging (MRI) technique to diagnose Parkinson’s disease at early stages.


The 18-month project, supported by a grant from the Center for Clinical and Translational Science in the U.K., will take place at the University of Kentucky’s College of Medicine under the leadership of George Quintero, PhD, and Zain Guduru, MD. It is expected to open this year...

Parkinson's

2020-03-25

Study to Test MRI Technique for Possible Early Parkinson’s Diagnosis
Parkinson’s Patients Have More Vision Problems, Require Better Screening, Study Says

Parkinson’s disease patients have a higher rate of vision problems compared with the general population, and require screening for ophthalmologic symptoms to enable more timely treatment, according to a recent study.


The study, “Seeing ophthalmologic problems in Parkinson disease,” was published in Neurology...

Parkinson's

2020-03-16

Parkinson’s Patients Have More Vision Problems, Require Better Screening, Study Says
Table Tennis Program May Ease Motor Symptoms in Parkinson’s, Early Study Shows

Table tennis may offer benefits as a form of Parkinson’s physical therapy, according to a preliminary study that showed lessening of symptoms in patients who participated weekly in the sport for six months...

Parkinson's

2020-02-28

Table Tennis Program May Ease Motor Symptoms in Parkinson’s, Early Study Shows
Imaging Analysis Software QyScore Receives FDA Clearance

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Qynapse‘s QyScore, a software that aids in analyzing brain scans taken by magnetic resonance imaging (MRI).

The software, which is compatible with routine imaging workflows, includes an advanced user interface and automatically-generated patient reports. Results are presented in comparison to data on people without known brain disease, giving neurologists and radiologists support in making clinical interpretations and decisions for treatment in a number of conditions, including Parkinson’s diseasemultiple sclerosis, and Alzheimer’s disease...

Parkinson's

2020-02-05

Imaging Analysis Software QyScore Receives FDA Clearance
About Me

Hi, I'm Tom, from whose brain these Deep Brain Thoughts flow! Thank you for visiting my blog, and keep coming back to enjoy future ramblings!

See my full profile >

© 2020 by Deep Brain Thoughts. Proudly created with Wix.com

Last Updated: 2019-04-10

Connect With Me

  • Facebook
  • Twitter
  • RSS